Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-BETA 1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma

Neoplasma

Volumn 51, Issue 6, 2004, Pages 481-486

  Morena, A M L ^a   Oshima, C T F ^a   Gebrim, L H ^a   Egami, M I ^a   Silva, M R R ^a   Segreto, R A ^a   Giannotti Filho, O ^a   Teixeira, V P C ^a   Segreto, H R C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast cancer; Erb B2; Immunohistochemistry; Tamoxifen; TGF beta 1; Tumor markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN LINKED KINASE; KI 67 ANTIGEN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ARTICLE; BREAST CARCINOMA; CELL NUCLEUS; CELL VOLUME; CHROMATIN CONDENSATION; DRUG EFFECT; GENE INDUCTION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 11144245919     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. ADAMS J, CARDER PJ, DOWNEY S, FORBES MA, BANKS E. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum and tissue VEGF microvessel density and effects of tamoxifen. Cancer Res 2000; 60: 2898-2905.
2. ATTWELL S, ROSKELLEY C, DEDHAR S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 2000; 33: 3811-3815.
3. BREIER G, BLUM S, PELI J, GROOT M, WILD C et al. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer 2002; 2: 142-148.
4. BURSCH W, HOCHEGGER K, TÖRÖK L, MARIAN B, ELLINGER A et al. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Science 2000; 113: 1189-1198.
5. BUTTA A, MACLENNAN K, FLANDERS KC, SPORN MB, BAUM M et al. Induction of transforming growth factor beta in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4264.
6. CAMERON DA, RITCHIE AA, MILLER WR. The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. Eur J Cancer 2001; 37: 1545-1533.
7. CHANG J, POWLES TJ, ALLRED DC, ASHLEY SE, MAKRIS A et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000; 6: 616-621.
8. CLARKE RB, LAIDLAW IJ, JONES LJ, HOWELL A, ANDERSON E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 1993; 67: 606-611.
9. DIHUA Y, MIEN-CHIE H. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19: 6115-6121.
10. DOWSETT M., ARCHER C, ASSERSOHN L, GREGORY RK, ELLIS PA et al. Clinical studies of apoptosis and proliferation in breast cancer. Endocrine-Related Cancer 1999; 6: 25-28.
11. FARCZÁDI E, KASZÁS I, BAKI M. Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment. Neoplasma 2002; 49: 101-103.
12. FOEKENS JA, PETERS HA, GREBENCHTCHIKOV N, LOOK MP, MEIJERVANGELDER ME et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 14: 5407-5414.
13. HEER K, KUMAR H, READ JR, FOX JN, MONSON JR, KERIN MJ. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 2001; 11: 3491-3494.
14. JANJI B, MELCHIOR C, VALLAR L, KIEFFER N. Cloning of a isoform of integrin-linked kinase (ILK) that is upregulated in HT-144 melanoma cells following TGF-beta1 stimulation. Oncogene 2000; 19: 3069-3077.
15. JORDAN VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994; 31: 41-52.
16. KUMAR R, YARMAND-BAGHERI R. The role of HER2 in angiogenesis. Semin Oncol 2001; 28 Suppl 16: 27-32.
17. LAKHANI SR, VAN DE VIJVER MJ, JACQUEMIER J, ANDERSON TJ, OSIN PP et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterona receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318.
18. MAJUMDAR SK, VALDELLON JA, BROWN KA. In vitro investigation on the toxicity and cell death induced by tamoxifen on two non-breast cancer cell types. J Biomed Biotechnol 2001; 1(3): 99-107.
19. MAKRIS A, POWLES TJ, DOWSETT M, OSBORNE CK, TROTT PA et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinoma. Clin Cancer Res 1977; 3: 593-600.
20. MARSON LP, KURIAN KM, MILLER WR, DIXON JM. The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res Treat 2001; (1): 9-15.
21. MASSAGUÉ J, BLAIN SW, LO RS. TGF beta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
22. MICHAELSON JS, SILVERSTEIN M, WYATT J, WEBWE G, MOORE R et al. Predicting the survival of patients with breast carcinoma using tumor size. Cancer 2002; 95: 713-723.
23. MICHELS JJ, DUIGOU F, MARNAY J, HENRY-AMAR M, DELOZIER T et al. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma. Cancer 2003; 97: 1376-1386.
24. MIYAZONO K, HELLMAN U, WERNSTEDT C, HELDIN CH. Latent high molecular weight complex of transforming growth factor beta1. J Biol Chem 1988; 263: 6407-6415.
25. PERRY RR, KANG Y, GREAVES B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and independent human breast cancer cells. Ann Surg Oncol 1995; 2(3): 238-245.
26. REISS M. TGF-beta and cancer. Microbes Infect 1999; (1): 1327-1347.
27. SAITO H, TSUJITANI S, OKA S, KONDO A, IKEGUCHI M et al. The expression of transforming growth factor beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999; 86: 1455-1462.
28. SHAO-CHUN W, KEISHI M, WEIYA X, JEONG SK, SEOCK-AH I et al. Doc-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through na Akt-independent pathway. Oncogene 2001; 20(47): 6960-6964.
29. SLAMON DJ, DEKERNION JB, VERMA IM. Expression of cellular oncogenes in human malignancies. Science 1984; 224(4646): 256-262.
30. SLEDGE GW. Implications of the new biology for therapy in beast cancer. Semion Oncol 1996; 23 Suppl 2: 76-81.
31. VAN DE VIJVER MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001; 37 Suppl 1: 11-17.
32. WHITE DE, CARDIFF RD, DEDHAR S, MULLER WJ. Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumor in transgenic mice. Oncogene 2001; 20(48): 7064-72.
33. WIESER R. The transforming growth factor-beta signaling pathway in tumorogenesis. Curr Opin Oncol 2001; 13(1): 70-77.
34. WU Y, SALDANA L, CHILLAR R. Plasma endotelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 2002; 20(3): 509-516.